News & Articles

Partnership strengthens IDT’s position as an NGS leader in China

The Thermo Scientific Solaris Orbital Shakers provide dependable performance and simplified operation in a compact benchtop design

Free up your time in the lab for the work that really matters

Experts share tips on how to choose between quaternary and binary UPLC systems in our webinar later on Thursday, July 11

Recommendation based on the results of IMpassion130 study in triple-negative breast cancer, an aggressive type of breast cancer with high unmet medical need

New vessel is designed for gentle stirring and optimum growth of cell lines

Find all the latest developments in antibody engineering and June’s top content from our drug discovery community

High capture efficiency and sensitivity of scATAC-Seq assay demonstrated in Nature Biotechnology study

Lab-based platform brings time resolution and synchrotron-level EUV analytics

From rare pathogens to pandemic prevention, explore the latest techniques and technologies that are shaping today’s diagnosis and treatment of infectious diseases

Fully authenticated and characterized materials to support reproducible research showcased

Invitrogen Collibri DNA Library Prep Kits for high-throughput Illumina systems offer real-time visual feedback to ensure workflow success

Learn about microfluidic diffusional sizing, a new technique for protein analysis, in this new on-demand webinar

Japan selects QIAGEN Clinical Insight-Interpret to handle next-generation sequencing data

Introduction of new MALDI Biotyper sirius™ system with additional negative-ion mode to support MALDI research and RUO validation studies, e.g. for colistin-resistance testing

Teaming with Persistent, the company realizes fast ROI as it develops technology to ensure reliable lab results and improve quality of patients’ lives

This novel antibody labeling immunoassay for multiplex immune profiling aims to address one of the fastest growing, billion-dollar life science market sectors

Based on ESCAPE™ RNA sequencing technology, the latest proteogenomics assay is designed to characterize both RNA and protein expression levels across thousands of single CAR T cells

Avacta’s first Affimer clinical candidate is a potent PD-L1 antagonist under development for solid tumor indications as the basis of bispecific and combination therapies